In lymph nodes, fibroblastic reticular cells (FRCs) form a collagen-based reticular network that supports migratory dendritic cells (DCs) and T cells and transports lymph. A hallmark of FRCs is their propensity to contract collagen, yet this function is poorly understood. Here we demonstrate that podoplanin (PDPN) regulates actomyosin contractility in FRCs. Under resting conditions, when FRCs are unlikely to encounter mature DCs expressing the PDPN receptor CLEC-2, PDPN endowed FRCs with contractile function and exerted tension within the reticulum. Upon inflammation, CLEC-2 on mature DCs potently attenuated PDPNmediated contractility, which resulted in FRC relaxation and reduced tissue stiffness. Disrupting PDPN function altered the homeostasis and spacing of FRCs and T cells, which resulted in an expanded reticular network and enhanced immunity.
In lymph nodes, fibroblastic reticular cells (FRCs) form a collagen-based reticular network that supports migratory dendritic cells (DCs) and T cells and transports lymph. A hallmark of FRCs is their propensity to contract collagen, yet this function is poorly understood. Here we demonstrate that podoplanin (PDPN) regulates actomyosin contractility in FRCs. Under resting conditions, when FRCs are unlikely to encounter mature DCs expressing the PDPN receptor CLEC-2, PDPN endowed FRCs with contractile function and exerted tension within the reticulum. Upon inflammation, CLEC-2 on mature DCs potently attenuated PDPNmediated contractility, which resulted in FRC relaxation and reduced tissue stiffness. Disrupting PDPN function altered the homeostasis and spacing of FRCs and T cells, which resulted in an expanded reticular network and enhanced immunity.
Lymph nodes (LNs) are highly organized structures that serve as 'rendezvous points' for dendritic cells (DCs), T lymphocytes and B lymphocytes. The maintenance of LN structure and compartmentalization are critical for generating effective immune responses and controlling unwanted immunological activation 1 . LNs increase vastly in size during immune responses and then must contract again upon resolution. Although lymphocyte proliferation and vascular remodeling contribute to this swelling [2] [3] [4] , the contributions of the reticular network have not been elucidated.
Fibroblastic reticular cells (FRCs) are LN-resident mesenchymal cells that secrete and remodel the extracellular matrix to create a dense reticular network. The FRC network serves as a scaffold for DCs and T cells to crawl on [5] [6] [7] [8] [9] and as a conduit for transporting lymph from the subcapsular sinus into the LN parenchyma 7, 10, 11 . A propensity to pull on collagen fibers and create tension is a hallmark of myofibroblasts. FRCs are specialized myofibroblasts in lymphoid organs with notable contractility 7, 8 ; however, the mechanistic basis and functional effects of this hallmark characteristic remain unknown. We hypothesized that the contractile function of FRCs might have a role in 'tuning' LN microarchitecture and immunity.
Podoplanin (PDPN; also known as gp38, Aggrus and T1a) is a transmembrane glycoprotein with high expression by FRCs, lymphatic endothelial cells (LECs) and various other cell types outside LNs 12 . It is critical during fetal development for blood-lymph separation and lung organogenesis [12] [13] [14] , and its overexpression in cancer correlates with increased invasion and metastasis 15 . However, a cell-autonomous function of PDPN in healthy adults has yet to be elucidated. PDPN is the endogenous ligand for the C-type lectin receptor CLEC-2 (CLEC1b) 16 , which is expressed by platelets and DCs. CLEC-2 signaling is critical for platelet activation 17 , the migration of activated DCs to draining LNs 18 and maintenance of vascular integrity and LN structure [19] [20] [21] . However, whether the engagement of CLEC-2 by PDPN results in signaling into the PDPN-expressing cell is unknown.
Here we elucidate the role of the PDPN-CLEC-2 interaction in FRC function. Under resting conditions, when FRCs are unlikely to encounter CLEC-2 in LNs due to a dearth of migratory DCs 22 , PDPN endows FRCs with the ability to exert tension within the reticular network. In this state, PDPN activates the actomyosin machinery of FRCs by engaging a neighboring transmembrane protein. Preventing PDPN signaling by the provision of CLEC-2, antibody blockade or genetic deficiency markedly attenuated the phosphorylation of myosin light chain (MLC) and contraction of FRCs. Loss of FRC contractility led to significant changes in the homeostasis and spacing of FRCs and T cells, with profound consequences for the LN microarchitecture and the population expansion of antigen-specific T cells following immunization.
Finally, as in two dimensions, PDPN-deficient FRCs covered a smaller area in three dimensions than did wild-type FRCs (Fig. 1e) .
Given that adhesion and spreading are related to cell contraction, we next used multiple approaches to investigate whether PDPN influences FRC contractility. First we treated FRCs with Y27632, an inhibitor of the kinase ROCK, a master regulator of contractility 24 . Y27632-treated FRCs exhibited extensive cell elongation similar to that of Pdpn -/-FRCs; however, Y27632-treated FRCs exhibited more protrusions than did Pdpn -/-FRCs ( Supplementary Fig. 1d-f) , which suggested that PDPN might signal through additional pathways. Next we directly assessed contractility by examining the contraction of three-dimensional collagen gels. Wild-type FRCs were much more efficient at contracting collagen than were Pdpn -/-FRCs (Fig. 1f) . Finally, as a third measure of contractility, we assessed the abundance of nuclear (active) YAP, a transcription factor reported to control contractility and promote the tumor-supporting functions of cancer-associated fibroblasts 25 . In agreement with the data obtained for collagen contraction, Pdpn -/-FRCs had significantly less nuclear YAP than did wild-type FRCs ( Fig. 1g and Supplementary Fig. 1g ). Together these results indicated that PDPN was a critical regulator of adhesion, elongation, and contraction in FRCs.
Molecular regulation of PDPN-mediated contractility
Next we sought to determine the mechanism underlying PDPN functions in FRCs. The only known proximal signaling mechanism by which PDPN might exert any direct effect on the cytoskeleton is through binding to and activating proteins of the ezrin, radixin, and moesin (ERM) family, which link membrane proteins to the cytoskeleton. In overexpression studies, PDPN was found to to interact with ERM proteins through a cluster of basic residues in the cytoplasmic In sum, our results identify PDPN as a master regulator of actomyosin contractility in FRCs. PDPN signaling maintained FRCs in a highly contracted state in healthy, resting organs. Upon an inflammatory response, the interaction between migratory DCs and FRCs allowed CLEC-2 to block PDPN, thereby attenuating contractility and relaxing the reticulum. Consequently, these microanatomical changes allowed the LN to increase in size and meet the spatial demands of the expanding lymphocyte pool.
RESULTS

Regulation of FRC actomyosin contractility by PDPN
To investigate the function of PDPN in LN FRCs, we initially isolated FRCs from wild-type mice and PDPN-deficient (Pdpn -/-) mice. While Pdpn -/-mice generally die soon after birth due to blood-lymph mixing and edema, when crossed onto a C57BL/6 background, approximately 20% of the mice thrive, and these served as a source of Pdpn -/-FRCs for our study 14 . FRCs from Pdpn -/-mice expressed normal amounts of canonical FRC markers, including PDGFRa and PDGFRb, CD44, a-smooth muscle actin and cadherin 11 ( Supplementary Fig. 1a) . We first investigated whether Pdpn -/-FRCs were defective in adhering to and spreading on collagen, as the converse has been reported for cancer cells that overexpress PDPN 23 . Indeed, Pdpn -/-FRCs were substantially impaired in both processes (Supplementary Fig. 1b,c) . Next we sought to investigate the effect of PDPN deficiency on the FRC cytoskeleton in collagen-based three-dimensional deformable matrices, which more closely simulate the LN microenvironment 18 . PDPN-deficient FRCs were elongated and extended F-actin-rich membrane protrusions (Fig. 1a,b) . Such protrusions were less abundant on Pdpn -/-FRCs than on wildtype FRCs; however, each protrusion extending from the cell body of Pdpn -/-FRCs was much longer than those of wild-type FRCs (Fig. 1c,d ). and Supplementary Fig. 3c ). Together these results indicated that PDPN expression maintained large amounts of activated ERM, MLC and RhoA, which endowed FRCs with contractile ability. When PDPN was genetically ablated, the global abundance of these activated factors was considerably reduced and thus FRCs were no longer able to adhere to collagen or generate tension within the reticular network.
Control of the proliferation and survival of FRCs by PDPN Stromal fibroblasts are exquisitely sensitive to the stiffness of the extracellular matrix they adhere to, which in turn affects their cytoskeletal contraction. Greater substrate stiffness results in tension in fibroblasts, which can affect their growth and survival 28 . Thus, we investigated whether the attenuated contractility in Pdpn -/-FRCs affected their proliferation or survival. Whereas the number of wild-type and Dcyto FRCs remained steady over a 4-day period, Pdpn -/-FRCs increased up to fourfold in number (Fig. 4a) . Pdpn -/-FRCs proliferated more extensively than did wild-type FRCs (Fig. 4b,c) and survived better than either wild-type FRCs or Dcyto FRCs (Fig. 4d,e) . Overall, these data demonstrated the involvement of PDPN signaling in regulating the growth and survival of FRCs.
tail of PDPN 23, 26 . To ascertain whether the PDPN-mediated control of actomyosin contractility in primary FRCs was mediated via this ERM-binding site, we generated knock-in mice in which PDPN lacking its cytoplasmic tail globally replaced fulllength PDPN (called 'Dcyto mice' here) (Supplementary Fig. 2a,b) . These mice were viable and did not exhibit any gross abnormalities. FRCs from LNs of Dcyto mice expressed normal amounts of PDPN, which did not become glycosylphosphatidylinositol anchored (Supplementary Fig. 2c-f) . Upon culturing Dcyto FRCs in three-dimensional matrices, we found that deletion of the nine-amino acid cytoplasmic tail was sufficient to recapitulate the elongated phenotype of the Pdpn -/-FRCs, with fewer and longer membrane protrusions than those of wildtype FRCs (Fig. 2a-d) . Unexpectedly, Dcyto FRCs were essentially identical to wild-type FRCs in contractility, showing no impairment in collagen contraction or difference in the amount of active YAP (Fig. 2e,f and Supplementary Fig. 2g ).
Having shown that direct binding of the PDPN cytoplasmic tail to ERM proteins was dispensable for actomyosin contractility in FRCs, we next sought to determine whether and to what extent key mediators of actomyosin contractility were affected by PDPN deficiency. Whereas localization of phosphorylated ezrin was unchanged (Fig. 3a) , the abundance of phosphorylated ERM in Pdpn -/-FRCs was 50% as much as that in wild-type or Dcyto FRCs ( Fig. 3b and  Supplementary Fig. 3a) . The degree to which the abundance of phosphorylated ERM was reduced in Pdpn -/-FRCs was especially striking given that these cytoskeletal linkers associate with multiple abundantly expressed transmembrane proteins. This idea, together with the finding that phosphorylated ERM abundance was normal in Dcyto FRCs, indicated that other domains of PDPN were sufficient to maintain global activation of ERM.
Next we investigated the subcellular localization of phosphorylated MLC, a key regulator of contractility. In wild-type and Dcyto FRCs, phosphorylated MLC largely localized together with actin filaments (Fig. 3c) . In contrast, and consistent with the data obtained for functional contraction, in Pdpn -/-FRCs, the phosphorylated MLC molecules were not associated with actin filaments; instead, they were more evenly distributed throughout the cell (Fig. 3c) . We confirmed that finding by immunoblot analysis, which indicated that the amount of phosphorylated MLC was diminished in Pdpn -/-FRCs but was similar in wild-type FRCs and Dcyto FRCs ( Fig. 3d and Supplementary Fig. 3b ).
Finally, we measured the abundance of active RhoA in FRCs. This small GTPase is downstream of ERM signaling but can also feed back to affect the activation of ERM proteins 27 . Additionally, RhoA functions upstream of MLC to control contraction 24 . Consistent with our contraction data, the amount of RhoA-GTP was lower in Pdpn -/-FRCs than in wild-type or Dcyto FRCs, which had similar amounts ( We also assessed the effect of PDPN deficiency on FRCs with Pdpn fl/fl Pdgfrb-Cre mice, in which loxP-flanked Pdpn alleles are deleted by Cre recombinase expressed from the gene encoding the receptor for plateletderived growth factor-b (Pdgfrb) and thus their FRCs lack PDPN 19 . Consistent with results obtained for mice treated with anti-PDPN, Pdpn fl/fl Pdgfrb-Cre mice exhibited larger LNs with greater total cellularity and a greater number of FRCs than did Pdpn fl/fl control mice (without expression of Pdgfrb-Cre) (Supplementary Fig. 5a-c) . However, we did not pursue additional studies of Pdpn fl/fl Pdgfrb-Cre mice due to their phenotype of bleeding related to a disruption in the integrity of high endothelial venules (HEVs) that has been previously reported 19 ( Supplementary Fig. 5d) .
Finally, we observed no difference between Dcyto mice and wildtype mice in LN mass, total cellularity, or number of FRCs ( Fig. 5f-h) . Additionally, we did not observe bleeding around HEVs in Dcyto mice (Supplementary Fig. 5e ). Given that FRCs cultured from these mice exhibited an elongation phenotype but normal contractility, these in vivo results indicated that FRC contractility was critical for maintaining normal LN size and number of FRCs.
anti-PDPN had slightly greater cellularity than those from mice treated with an isotype-matched control antibody, this was not concomitant with the enhanced mass (Fig. 5a,b) . These findings led us to question whether the stiffness of the LN was altered. Using a standard compression test, we found that LNs from wild-type mice were significantly less stiff and more deformable following antibody blockade of PDPN than after treatment with an isotype-matched control antibody (Fig. 5c) .
Next we sought to determine whether FRCs would respond to the relaxation noted above by increasing in number as they did in vitro. Two days after the administration of antibody to wild-type mice, the number of FRCs that had incorporated the thymidine analog BrdU (proliferating FRCs) and, accordingly, the total number of FRCs were significantly greater in mice treated with monoclonal antibody 8.1.1 than in their counterparts treated with an isotype-matched control antibody (Fig. 5d,e) . Additionally, FRCs in mice treated with anti-PDPN were much larger than those in mice treated with an isotypematched control antibody (Supplementary Fig. 4h,i) , consistent with a blasting phenotype. binding of CLEC-2-Fc (CLEC-2 linked to a rabbit Fc fragment) to FRCs or affect DC numbers in steady-state or inflammatory conditions ( Supplementary Fig. 6a-c) . At 96 h after immunization with LPS and OVA, we found a significantly greater number of OT-I T cells in LNs treated with anti-PDPN than in those treated with an isotype-matched control antibody (Fig. 6a) . Accordingly, at 48 h after immunization, divided OT-I T cells were more abundant in LNs treated with anti-PDPN than in those treated with the isotype-matched control antibody (Fig. 6b) .
FRCs suppress the proliferation of activated T cells through cell-cell contact [30] [31] [32] [33] . Given that we observed greater spacing between FRCs after blockade of PDPN, we investigated whether there was a change in the number of T cells touching FRCs in the mice treated with anti-PDPN. Indeed, fewer T cells were in contact with the FRC network after blockade of PDPN than after treatment with the isotype-matched control antibody (Fig. 6c) ; this may have contributed to the increased T cell response. Overall, these findings indicated that PDPN-mediated control of FRC contractility was critical for restraining LN swelling and T cell responses.
Inhibition of FRC contraction by CLEC-2 engagement of PDPN PDPN + FRCs come into contact with CLEC-2 on migratory DCs and platelets 18, 19, 21 , which raises the question of how binding of CLEC-2 to PDPN affects FRCs. To determine if CLEC-2 transmits a signal to FRCs, we cultured wild-type FRCs in three-dimensional matrices and incubated them with soluble CLEC-2-Fc or, as a control, rabbit immunoglobulin G (IgG). Within 3 h, the FRCs became elongated, and by 12 h, they closely resembled Pdpn -/-FRCs (Fig. 7a,b) . CLEC-2-Fc or rabbit IgG had no effect on the elongation of Pdpn -/-or Dcyto FRCs (Supplementary Fig. 7a ), as expected, because FRCs do not express Fc receptors 4 . In addition, treatment with CLEC-2-Fc impaired the spreading of FRCs on collagen (Supplementary Fig. 7b ). To determine whether the same effect could be achieved with CLEC-2 naturally expressed by cells, we cultured wild-type FRCs together with LPS-activated wild-type or CLEC-2-deficient (Clec1b -/-) bone marrow-derived DCs (BMDCs) or with wild-type or Clec1b -/-platelets. Notably, CLEC-2 + DCs and platelets induced elongation of FRCs to a degree similar to that induced by soluble CLEC-2-Fc (Fig. 7c,d ). CLEC-2-Fc also induced clustering of PDPN and the formation of PDPN-rich protrusions (Fig. 7e,f) . Thus, we investigated whether this elongation was dependent on actin polymerization. Indeed, treatment with cytochalasin D at a concentration that preserved cytoskeletal integrity significantly diminished the elongation of FRCs elicited by CLEC-2-Fc (P = 0.0117; Supplementary Fig. 7c ).
The finding that CLEC-2 had the same effect on FRCs as PDPN deficiency had prompted us to assess whether binding of CLEC-2 inhibited contractility. The binding of CLEC-2 to wild-type and Dcyto FRCs caused a significant reduction in collagen contraction and the Expansion of the FRC network upon blockade of PDPN Next we sought to define the role of PDPN in the LN FRC network. First, we investigated conduit function by injecting the tracer fluorescein isothiocyanate into the footpads of mice treated with isotype-matched control antibody or anti-PDPN and collecting the popliteal LNs 4 h later. We noted no obvious abnormalities in access of the tracer to conduits in either the paracortex or cortical regions beneath the subcapsular sinus in mice treated with anti-PDPN (Supplementary Fig. 5f ).
Next we investigated the effect of PDPN blockade on the structure of the FRC network. For this we used Rosa26-eYFP fl/fl Ccl19-Cre mice, in which Cre expressed by the locus encoding the chemokine CCL19 drives the excision of a transcriptional stop sequence before the gene encoding enhanced yellow fluorescent protein (eYFP) inserted into the ubiquitous Rosa26 locus, which results in expression of eYFP only in FRCs 29 . We treated these mice with anti-PDPN or an isotype-matched control antibody. Confocal microscopy combined with three-dimensional reconstruction and isosurface rendering revealed that the network had a finer appearance with more space between fibers in Rosa26-eYFP fl/fl Ccl19-Cre mice treated with anti-PDPN than in those treated with the isotype-matched control antibody (Fig. 5i) . Quantitative analysis confirmed that the surface area of FRCs and an extracellular matrix component they secrete, ER-TR7, was lower in LNs from mice treated with anti-PDPN than in those from mice treated with isotype-matched control antibody (Fig. 5i-k) . We observed changes to the FRC network in Pdpn fl/fl Pdgfrb-Cre mice that were similar to those in mice treated with anti-PDPN (Supplementary Fig. 5g-i) . Finally, and consistent with our observations that LN mass and FRC numbers remained unchanged upon deletion of the PDPN cytoplasmic tail, the network structure in Dcyto LNs was similar to that in wild-type LNs (Fig. 5l-n) .
To determine whether FRCs were further apart from each other, we analyzed nuclear distance by measuring the distance to the closest neighboring FRC nucleus. FRCs were closer to each other in LNs of mice treated with isotype-matched control antibody than in those of mice treated with anti-PDPN ( Fig. 5o and Supplementary Fig. 5j,k) . Thus, the stromal relaxation that occurred upon attenuation of PDPNmediated contractility led to LN enlargement and expansion of the FRC network.
Restraint of T cell responses by PDPN-mediated contractility
We next addressed how blocking PDPN function and FRC contractility would affect an immune response. For this, we treated wild-type mice with anti-PDPN or an isotope-matched control antibody, followed 2 d later by injection of OT-I CD8 + T cells (which have transgenic expression of an ovalbumin (OVA)-specific T cell antigen receptor) labeled with the cytosolic dye CFSE and immunization with lipopolysaccharide (LPS) and OVA. Notably, the PDPN-specific antibody did not block We found that injection of wild-type BMDCs significantly increased LN mass, as previously described 33 , but injection of Clec1b -/-BMDCs led to significantly less LN swelling in mice that received Clec1b -/-BMDCs than in those that received wild-type BMDCs, at each time point examined (Fig. 8a) . However, the impaired recruitment of CLEC-2-null cells is transient, and the number of wild-type DCs and Clec1b -/-DCs in draining LNs is no longer different as early as 3 d after injection 18 . Therefore, the finding that LN mass remained significantly lower 5 d after DC injection, when equal numbers of wild-type and Clec1b -/-migratory DCs are present in LNs, should be interpreted as an absence of CLEC-2 signaling, rather than impaired DC recruitment. This notion supports our hypothesis that an inhibitory signal from CLEC-2 on migratory DCs is required for LN expansion.
Next we hypothesized that a lack of CLEC-2 during an immune response would prevent the expansion of LNs and T cell proliferation. amount of YAP localized to the nucleus, as we observed in Pdpn -/-FRCs (Fig. 7g-i and Supplementary Fig. 7d,e) . The finding that CLEC-2 reduced contractility to the same extent in Dcyto FRCs and wild-type FRCs was consistent with the proposal that the extracellular domain of PDPN mediates contractility through lateral membrane interactions and that CLEC-2 disrupts these interactions to block PDPN function.
Finally, we assessed whether engagement of CLEC-2 by PDPN caused a decrease in active ERM and MLC similar to deficiency in PDPN. Treatment of wild-type FRCs with CLEC-2-Fc caused a rapid and substantial decrease in both phosphorylated ERM and phosphorylated MLC (Fig. 7j,k and Supplementary Fig. 7f,g) . Thus, the finding that CLEC-2 delivered a signal to FRCs that recapitulated the effects of genetic PDPN deficiency suggested that CLEC-2 acts as an inhibitor of PDPN function.
Requirement for CLEC-2 in LN expansion following immunization
Having shown that antibody blockade of PDPN led to increased LN swelling in the steady state and T cell proliferation following immunization and that CLEC-2 inhibited PDPN, we sought to determine whether Fig. 3b-e) . Each symbol represents an individual cell (b-d,h,i) or collagen gel (g); small horizontal lines indicate the mean (± s.d.). *P < 0.05, **P < 0.01, ***P < 0.001 and ****P < 0. with our hypothesis, after only 1 h, LNs of mice treated with CLEC-2-Fc were significantly larger than those of mice treated with rabbit IgG and, at 4 h, the LNs had already returned nearly to their baseline weight (Fig. 8j) . This finding was not due to an influx of cells or inflammation ( Supplementary Fig. 7h-l) . LECs also express PDPN, which raises the possibility that the CLEC-2 signal might alter vascular integrity. However, while Pdpn -/-LECs were elongated compared with wild-type LECs, unlike FRCs, wild-type LECs did not respond to soluble CLEC-2 by elongating (Supplementary Fig. 7m) . Furthermore, injection of anti-PDPN did not lead to changes in lymphatic pulsatile activity at early (1 h) or late (48 h) time points (data not shown), which suggested that the in vivo effects of PDPN blockade were not attributable to global alterations in lymph flow. However, in LNs treated with CLEC-2-Fc, FRCs were disorganized, particularly around HEVs ( Supplementary  Fig. 7n) . Thus, CLEC-2-Fc-induced relaxation of FRCs may alter HEV integrity and allow blood or plasma to enter LNs. (Fig. 8b,c) . As expected, this observation was due to the decreased number of migratory DCs entering into the LNs and the dampened T cell response in Clec1b fl/fl Cd11c-Cre mice relative to that in Clec1b fl/fl mice (Fig. 8d,e) .
Next we sought to determine whether a lack of CLEC-2 would impair expansion of the FRC network. While FRC numbers increased following immunization with LPS, this increase was dampened when the CLEC-2 signal from DCs was absent (Fig. 8f) . Furthermore, as we had observed in mice treated with anti-PDPN (Fig. 5i) , the FRC network significantly expanded in Clec1b fl/fl control mice upon immunization (Fig. 8g-i) . Notably, while there was no significant difference between PBS-treated Clec1b fl/fl mice and PBS-treated Clec1b fl/fl Cd11c-Cre mice in their FRC networks, the LPS-induced expansion of the network was abolished in Clec1b fl/fl Cd11c-Cre mice (Fig. 8g-i) . These results confirmed published findings that a lack of CLEC-2 impairs the arrival of DCs in draining LNs and dampens immune responses 18 . Furthermore, we advanced those findings by demonstrating that the FRC network expanded to accommodate increasing LN size and that this expansion required a CLEC-2 signal from DCs. While in this setting the effect CLEC-2 deficiency cannot be separated from that of impaired DC migration, these results nevertheless supported our findings obtained with the PDPN-specific antibody.
As a final assessment of whether CLEC-2 itself delivers a signal to relax the FRC network, we injected CLEC-2-Fc intravenously into wildtype mice and examined LNs at 1 h and 4 h after injection. Consistent Inflammation is known to trigger FRC proliferation; however, the timing and extent of division appears to vary between inflammatory stimuli, and the specific underlying mechanisms remain unknown 4, 34, 47 . Our data indicated that the relaxation of FRCs allowed early LN expansion in addition to providing a signal for proliferation, which caused FRCs to accumulate and accommodate the expanding organ. While a published study did not report changes in LN architecture 47 , we observed expansion of the FRC network upon immunization, as reported before 34 . This discrepancy could be due to differences in the timing or types of immunization used. It has been noted that PDPN amounts increase in response to select inflammatory stimuli 47, 48 (data not shown), which may restore high contractility to FRCs upon resolution of inflammation. Our results demonstrated that this process was crucial for FRC-mediated restraint of T cell proliferation.
Together, these data indicate that CLEC-2 + DCs provide a fast but reversible signal to PDPN + FRCs. This allows transient relaxation of the FRC network that would persist only as long as CLEC-2 + DCs were crawling along the network. Ultimately, normal contraction of FRCs would resume shortly after removal of the CLEC-2 signal (and increased PDPN expression), which would occur as the immune response began to wane and migratory DCs perished in the draining LN. Reestablishment of FRC contractility would enable structural and functional homeostasis in the reticular network to be restored.
METHODS
Methods and any associated references are available in the online version of the paper. Collectively, these data indicated that CLEC-2 inhibited PDPN function and caused FRCs to relax. This relaxation led to increased spacing in the paracortical reticular network and allowed LNs to expand. However, upon attenuation of the CLEC-2 signal, FRCs regained their contractile ability, which restored normal LN size and microarchitecture (Supplementary Fig. 8 ).
DISCUSSION
Here we have identified PDPN as a master regulator of the contractile force generated by FRCs and have elucidated a critical function for FRC contractility in maintaining LN microarchitecture. Under non-inflammatory conditions, PDPN maintained FRCs in a highly contracted state. Disruption of PDPN-mediated contractility caused LN enlargement in part via relaxation and expansion of the FRC network. Unexpectedly, these changes did not affect conduit permeability, in line with a published report demonstrating prolonged conduit function following ablation of FRCs 35 .
Notably, we discovered that CLEC-2 inhibited PDPN signaling in FRCs. Published studies of the PDPN-CLEC-2 interaction have focused on signaling downstream of CLEC-2 (refs. 18, 19, 21) . Here we have demonstrated that signaling also occurred downstream of PDPN and that its engagement of CLEC-2 on DCs diminished FRC contractility. CLEC-2 seemed to deliver a rapid and transient inhibitory signal to FRCs. The affinity of the binding of CLEC-2 to PDPN is 24.5 mM (ref. 16 ), whereas a high-affinity antibody can be in the nanomolar or even picomolar range 36 . Furthermore, within minutes of engaging soluble PDPN, CLEC-2 is internalized 18 . Thus, the inhibition of PDPN caused by migratory DCs would probably be quickly relieved.
Our finding that the cytoplasmic tail of PDPN was dispensable for FRC contractility was unexpected and suggested that its extracellular or transmembrane domains mediate this hallmark function. Indeed, the interaction of PDPN with CD44 and galectin-8 regulates cell migration and adhesion 37, 38 . Furthermore, PDPN interacts with CD9, a tetraspanin that modulates integrin signaling 39 . Furthermore, the transmembrane domain of PDPN is required for its localization to lipid rafts 40 , where CD44 is also retained upon the differentiation of fibroblasts into myofibroblasts mediated by transforming growth factor-b 41 . Additionally, our findings obtained with Dcyto FRCs indicating that the PDPN cytoplasmic tail was required for FRC elongation despite the finding that Dcyto FRCs had normal levels of activated ERM proteins suggested that the cytoplasmic tail has other signaling mechanisms. In fact, two serine residues in the PDPN tail can be phosphorylated 42 . To what extent these interactions regulate FRC function and LN microarchitecture remains unclear. The finding that CLEC-2 inhibited contraction to the same extent in Dcyto FRCs and wild-type FRCs suggested that CLEC-2 mediates its effect by preventing the extracellular domain of PDPN from interacting in cis with a lateral binding partner.
Similar to its action in FRCs, PDPN controls elongation and activation of RhoA in LECs 43 ; however, LECs differed from FRCs in that LECs did not elongate upon binding CLEC-2. Furthermore, we found that bulk lymph flow and access of lymph to conduits were not altered upon in vivo blockade of PDPN. Given our results and the fact that LECs are not highly contractile, it is unlikely that PDPN expressed by LECs has a role in LN expansion and reticular architecture.
Cell contractility and sensing of matrix stiffness regulate the differentiation, migration and survival of fibroblasts 44 . The balance between the adhesion of a cell to a substrate of a given stiffness and the resulting tension within that cell determines overall tensional homeostasis 44, 45 . Disruption of this balance, whether by changes in matrix stiffness or by changes in contractile potential, alters fibroblast proliferation 46 . Thus, the increased proliferation and survival that we observed for Pdpn -/-FRCs might have stemmed from dysregulated adhesion or tension or both.
